biotech usa magnesium

Solarvest to Launch a Suite of Products in China and USA

(TheNewswire)



TheNewswire - October 6 th 2021 Solarvest BioEnergy Inc. ( " Solarvest ", or the "Company" ) (TSXV:SVS), is pleased to report, that through its wholly owned subsidiary Eversea, the launch of a Chinese social media promotion program and the development of a line of products for distribution in the USA and through OrgHive in China. The products include the company's proprietary organically produced and FDA NDI #861 approved Omega-3 as the foundation for the entire range of products.  The four new blended powder products are Daily Omega, Stamina, Recovery and Vision.  All are formulated to supplement the essential daily Omega-3 requirement with added functional organic ingredients. For example, Stamina includes ingredients that are known to dilate blood vessels, an effect that can lower blood pressure and increase exercise time to task failure.  Recovery includes ingredients that, in addition to Omega-3, are known to reduce inflammation. The company will also launch its children's organically certified dried fruit gummy in China.  These products are ideal for the approximate 300 million Chinese middle-class consumers who are driven to imported and organically certified products.  These products assuage their concerns about locally produced products and food due to soil contamination and overuse of agriculture chemicals.


Click Image To View Full Size

Orghive uses Blockchain technology to give customers conformation that the certification "organic" have actually been approved by regulators – not counterfeit.  In China, the misuse of the qualifying term "organic" has made consumers wary of the classification.  This technology will allow them to purchase organic products with instant mobile verification knowing they have been properly approved by reputable organic certifiers.  In North America some of the largest platforms do not protect consumers from any company using "organic" as their search terms for their Omega-3 products.  The OrgHive platform goes a long way to correct this confidence deficit through blockchain technology for its customers.

About OrgHive:

The OrgHive organic community has garnered 23 million unique users since inception last year. They provide organic related content to consumers online and have developed a blockchain-based verification system for organic products that are purchased throughout mainland China. Furthermore, the platform developed by OrgHive will reach organic consumers beyond China, including those located in other parts of Asia.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully developed, patented and produced the world's only plant-based organic certified Omega-3 to satisfy the substantial demand for this essential nutrient.  The company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers

Overall Survival Data from Phase 3 LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) in Metastatic Colorectal Cancer Accepted as Late-Breaking Oral Presentation

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels

Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire ® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant (90% CI: -6, 36; p[1-sided]=0.1042). The results will be featured in presentations at the American Thoracic Society (ATS) International Conference, May 17-22 in San Diego .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

FDA APPROVES IMDELLTRA , THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday May 20, 2024 following the presentation of new data from TEZSPIRE ® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, and other members of the Amgen team will participate. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Nutura Organic Ltd – Term Sheet to commence Pilot Study

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company has entered into a legally binding Term Sheet (Term Sheet) with Australian-based company Nutura Organic Ltd (Nutura) for the purchase of adult milk formula to enable the Company to undertake a pilot study in China.

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less

Latest Press Releases

Related News

×